Allogene Therapeutics Earnings Preview
Portfolio Pulse from Benzinga Insights
Allogene Therapeutics (NASDAQ:ALLO) is expected to report a Q4 earnings per share (EPS) of $-0.45 on March 14, 2024. Historical data shows the company has previously beaten EPS estimates, leading to significant share price movements. Shares are currently trading at $4.9, down 10.44% over the last year. Investors will be closely watching for earnings performance and future guidance.
March 13, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics is anticipated to report a Q4 EPS of $-0.45. Historical performance shows potential for significant price movement post-earnings. Currently trading at $4.9, down 10.44% over the last year.
Given Allogene Therapeutics' history of beating EPS estimates and the subsequent positive share price reactions, there is a strong potential for a positive short-term impact on ALLO's stock price if the company beats the EPS estimate again and provides optimistic future guidance. However, the current year-to-date negative performance indicates investor caution.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100